The combination therapy of neratinib (an EGFR/ERBB2 inhibitor) and cobiotinib (a MEK inhibitor) exhibited synergistic anti-tumor proliferation exclusively in organoids derived from patients with high KDS30 mt KRAS rather than low ones. This evidence concerns the gene MAP2K7 and neoplasm.